View by Specialty

Trending

PC0924Houry_Graphic_01_WEB
September 11, 2024
4 min read
Save

CDC data reveal three social drivers that influence suicide risk

Stomach/Duodenum News

SPONSORED CONTENT
Save
SPONSORED CONTENT
January 26, 2024
2 min read
Save

Investigation links Salmonella outbreak to pet bearded dragons

Investigation links <i>Salmonella</i> outbreak to pet bearded dragons

An investigation into a Salmonella outbreak in Canada linked to pet bearded dragons revealed a multinational outbreak that included a dozen cases in the United States in 2021 and 2022, researchers reported.

SPONSORED CONTENT
January 19, 2024
1 min read
Save

Salmonella cases double as CDC expands warning on charcuterie meats


  <i>Salmonella</i> cases double as CDC expands warning on charcuterie meats

The CDC expanded its warning on eating charcuterie meats after the number of cases in a multistate Salmonella outbreak doubled over the last 2 weeks.

Trending

PC0924Houry_Graphic_01_WEB
September 11, 2024
4 min read
Save

CDC data reveal three social drivers that influence suicide risk

SPONSORED CONTENT
December 14, 2023
1 min read
Save

Perceived stress, gastrointestinal factors linked to menopause symptoms

Perceived stress, gastrointestinal factors linked to menopause symptoms

Perceived stress and certain gastrointestinal factors were linked to menopausal symptoms, with reproductive stages, physical activity, BMI and previously diagnosed depression or anxiety affecting symptom severity, researchers reported.

SPONSORED CONTENT
November 29, 2023
3 min read
Save

Joint statement calls for FDA to require drug trials to include people with obesity

Joint statement calls for FDA to require drug trials to include people with obesity

Five obesity advocacy organization have issued a joint statement asking the FDA to mandate that all drug approval trials include people with obesity.

SPONSORED CONTENT
November 08, 2023
2 min read
Save

Tirzepatide earns FDA approval for obesity treatment

Tirzepatide earns FDA approval for obesity treatment

The FDA approved the injectable GIP/GLP-1 dual incretin-based agonist tirzepatide for chronic weight management among adults with obesity, according to a press release.

SPONSORED CONTENT
November 07, 2023
2 min read
Save

Vagal nerve stimulation reduces need for rescue medication in gastroparesis, dyspepsia

Vagal nerve stimulation reduces need for rescue medication in gastroparesis, dyspepsia

VANCOUVER, British Columbia — As-needed vagal nerve stimulation reduced rescue mediation use among patients with nausea related to gastroparesis or functional dyspepsia, according to data presented at the ACG Annual Scientific Meeting.

SPONSORED CONTENT
October 26, 2023
1 min read
Save

FDA grants MR conditional use to Enterra’s electrical stimulation device for gastroparesis

FDA grants MR conditional use to Enterra&rsquo;s electrical stimulation device for gastroparesis

The FDA has granted conditional use with magnetic resonance imaging to Enterra Medical’s implantable electrical stimulation device for management of symptoms associated with gastroparesis, according to a company release.

SPONSORED CONTENT
October 24, 2023
2 min read
Save

Tirzepatide 15 mg is the ‘most efficacious’ for weight loss among GLP-1 agonists

Tirzepatide 15 mg is the &lsquo;most efficacious&rsquo; for weight loss among GLP-1 agonists

VANCOUVER, British Columbia — Tirzepatide 15 mg was associated with the highest degree of weight loss compared with other glucagon-like peptide-1 agonists and placebo, according to a presenter at the ACG Annual Scientific Meeting.

SPONSORED CONTENT
October 21, 2023
2 min read
Save

Apraglutide reduces parenteral support needs in patients with short bowel syndrome

Apraglutide reduces parenteral support needs in patients with short bowel syndrome

Treatment with apraglutide resulted in a 52% reduction in weekly parenteral support volume at 1 year among nine patients with short bowel syndrome with intestinal failure and colon-in-continuity, according to data presented at UEG week.

SPONSORED CONTENT
August 23, 2023
3 min read
Save

Larger HbA1c drop in type 2 diabetes treated with semaglutide vs. other GLP-1 agents

Larger HbA1c drop in type 2 diabetes treated with semaglutide vs. other GLP-1 agents

Semaglutide conferred greater reductions in HbA1c and body weight among adults with type 2 diabetes than other GLP-1 receptor agonists, according to findings from a systematic review and meta-analysis.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails